Quickly optimizing therapy
for patients with life-threatening infections is critical. Hours count, and you've been waiting for days. You need answers...
MicroPhage provides
answers to clinicians seeking to optimize antibiotic therapy earlier in the course of disease. MicroPhage products are dedicated to improving patient outcomes, decreasing length of hospital stay and enhancing antimicrobial stewardship.News:
April 2012:
- MicroPhage KeyPath™ Test Receives Expanded Clearance
- KeyPath™ now available for purchase.
- MicroPhage partners with Cardinal Health to market KeyPath™ in North America
- Cardinal Health Provides commercialization funding for initial MicroPhage products.
Events:
- 3/22/2012 SCACM
- 4/10/2012 CLCC
- 4/13/2012 NYCASM
- 5/1/2012 ASCLS-CNE
- 5/12/2012 MAD-ID
- 5/21/2012 NACMID
- 6/17/2012 ASM
Literature:
- Case for Accelerated Susceptibility Testing in the Era of Antibiotic Resistance
- Controlled Multicenter Evaluation of a Bacteriophage Based Method for the Rapid Detection of S. aureus in Positive BCs
- KeyPath™ MRSA/MSSA Blood Culture Test – BT Accurately Identifies S. aureus Isolates of Broad Phylogenetic Diversity
- FDA News Release on KeyPath™